5.20
-0.95%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ixensor Co
Its shares trade on Taipei Exchange under the ticker 6734.TWO. It has been listed since 28 June 2019. In the fiscal year to 31 December 2025, it reported revenue of TWD 26.9m and a net loss of TWD 47.0m. At that date it held total assets of TWD 69.0m and shareholders' equity of TWD 23.1m.
iXensor Co., Ltd. engages in integrated self-monitor blood glucose medical device and diabetes management services. The company is headquartered in Taipei City, Taipei. The company went IPO on 2019-06-28. The firm's innovative technology platform can be used to measure biochemical parameters such as luteinizing hormone, blood sugar, glycated hemoglobin, total cholesterol, high-density cholesterol, triglycerides, myocardial infarction enzymes, and other immune response parameters, such as female hormone cycle changes, infectious diseases and others. The firm's products include PixoTest Blood Glucose Monitoring System, ovulation detection system and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 28 Jun 2019
- Website
- ixensor.com ↗
Leadership
Pay as last reported
- Mr. Carson ChenChairman of the Board, General Manager
- Mr. Patrick LiaoDeputy General Manager-Marketing
- Hanlin ChenChief Commercial Officer (Senior Vice President- Marketing and Sales)
- Mr. Jerry ChenChief Medical Officer, since 2020
- Shulan HuangHead of Finance & Accounting
- Mr. Peter FitzgeraldDirector, since 2020
- Shuqi GuoDirector
- Yunxiang QiuDirector
- Yiwen LaiIndependent Director
- Mr. Zhijie ZhongIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PixoTest Blood Glucose Monitoring System offers accurate blood sugar measurements for diabetes management.
- iXensor's technology platform measures multiple biochemical parameters including luteinizing hormone and cholesterol levels.
- The company's innovative services provide comprehensive diabetes management solutions in Taipei City.
Weaknesses
- The firm's IPO on 28 June 2019 may limit access to capital for expansion.
- iXensor's focus on Taipei City restricts market reach beyond Taiwan.
- Limited product range compared to global competitors in Health Care sector.
Opportunities
- Expanding into international markets for diabetes management services outside Taiwan.
- Increasing demand for blood glucose monitoring systems in the Health Care industry.
- Leveraging technology platform for new applications in immune response parameters.
Threats
- Competition from established global Health Care companies in diabetes management.
- Regulatory changes in Taiwan affecting medical device approvals.
- Economic downturns impacting healthcare spending in the Taipei City market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.